2010 publi_docx

Année 2010
Travaux :
Service d’Hématologie Clinique et Thérapie Cellulaire
& Unité de Recherche Clinique Hématologie
Réseau Hématolim
Publications
Lenalidomide in combination with melphalan and dexamethasone in patients with
newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.
Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, Salles G, Leblond V,
Roussel M, Alakl M, Hermine O, Planche L, Harousseau JL, Fermand JP.
Blood. 2010, 116(23):4777-82.
Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.
Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, Rostaing L,
Saint Marcoux F, Essig M, Rerolle JP, Cotin S, Germi R, Pillet S, Lebranchu Y, Turlure P,
Alain S; French CMV Resistance Survey Study Group.
J Antimicrob Chemother. 2010, 65(12):2628-40.
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to
myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54
cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F,
Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat
C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).
Blood. 2010,116(19):3735-42.
Early introduction of ESA in low risk MDS patients may delay the need for RBC
transfusion: a retrospective analysis on 112 patients.
Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C,
Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP,
Fenaux P, Dreyfus.
Leuk Res. 2010, 34(11):1430-6.
Involvement of Human Herpesvirus-6 Variant B in Classic Hodgkin's Lymphoma via
DR7 Oncoprotein.
Lacroix A, Collot-Teixeira S, Mardivirin L, Jaccard A, Petit B, Piguet C, Sturtz F, Preux
PM, Bordessoule D, Ranger-Rogez S.
Clin Cancer Res. 2010,16(19):4711-21.
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study
comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a
study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S,
Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H.
Blood. 2010,116(12):2040-5.
Endonasal trans-ethmoidal drainage of a cerebral abscess.
Patron V, Orsel S, Caire F, Turlure P, Bessède JP, Aubry K.
Skull Base. 2010, 20(5):389-92.
Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of
chronic myeloid leukemia patients to imatinib mesylate therapy.
Lippert E, Etienne G, Mozziconacci MJ, Laibe S, Gervais C, Girault S, Gachard N, Tigaud
I, Dastugue N, Huguet F, Fort MP, Legros L, Eclache V, Mahon FX.
Haematologica. 2010, 95(9):1604-7.
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations
in acute myeloid leukemia: a study by the Acute Leukemia French Association
group.
Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D,
Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X,
Castaigne S, Dombret H, Preudhomme C.
J Clin Oncol. 2010, 28(23):3717-23.
Tandem versus single autologous peripheral blood stem cell transplantation as
post-remission therapy in adult acute myeloid leukemia patients under 60 in first
complete remission: results of the multicenter prospective phase III GOELAMS LAM-
2001 trial.
Chevallier P, Fornecker L, Lioure B, Béné MC, Pigneux A, Recher C, Witz B, Fegueux N,
Bulabois CE, Daliphard S, Bouscary D, Vey N, Delain M, Bay JO, Turlure P, Bernard M,
Himberlin C, Luquet I, Ifrah N, Harousseau JL; GOELAMS.
Leukemia. 2010, 24(7):1380-5.
Does iron chelation therapy improve survival in regularly transfused lower risk MDS
patients? A multicenter study by the GFM (Groupe Francophone des
Myélodysplasies).
Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus
F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P; GFM (Groupe
Francophone des Myélodysplasies).
Leuk Res. 2010, 34(7):864-70.
Daily practice management of myelodysplastic syndromes in France: data from 907
patients in a one-week cross-sectional study by the Groupe Francophone des
Myelodysplasies.
Kelaidi C, Stamatoullas A, Beyne-Rauzy O, Raffoux E, Quesnel B, Guerci A, Dreyfus F,
Brechignac S, Berthou C, Prebet T, Hicheri Y, Hacini M, Delaunay J, Gourin MP, Camo
JM, Zerazhi H, Taksin AL, Legros L, Choufi B, Fenaux P; Groupe Francophone des
Myélodysplasies.
Haematologica. 2010, 95(6):892-9.
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in
patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Raffoux E, Cras A, Recher C, Boëlle PY, de Labarthe A, Turlure P, Marolleau JP, Reman
O, Gardin C, Victor M, Maury S, Rousselot P, Malfuson JV, Maarek O, Daniel MT, Fenaux
P, Degos L, Chomienne C, Chevret S, Dombret H.
Oncotarget. 2010, 1(1):34-42.
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic
thrombotic microangiopathies: the French TMA reference center experience
Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S,
Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J,
Girault S, Bordessoule D, Saheb S, Ramakers M, Hamidou M, Vernant JP, Guidet B,
Wolf M, Veyradier A; French Reference Center for Thrombotic Microangiopathies.
PLoS One. 2010, 5(4).
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell
lymphoma
Troutaud D, Petit B, Bellanger C, Marin B, Gourin-Chaury MP, Petit D, Olivrie A,
Feuillard J, Jauberteau MO, Bordessoule D.
Clin Lymphoma Myeloma Leuk. 2010, 10(2):118-24.
Very long-term outcome of acute promyelocytic leukemia after treatment with all
trans retinoic acid and chemotherapy: the European APL Group experience.
Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X,
Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C,
Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L,
Chevret S, Fenaux P; European APL Group
Blood. 2010, 115(9):1690-6.
Randomized study of intensified anthracycline doses for induction and recombinant
interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70
years: results of the ALFA-9801 study.
Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis JH, Reman O,
Turlure P, Contentin N, de Revel T, Rousselot P, Preudhomme C, Bordessoule D,
Fenaux P, Terré C, Michallet M, Dombret H, Chevret S, Castaigne S.
J Clin Oncol. 2010, 28(5):808-14.
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the
prerituximab era: effect of response quality on survival--A study from the groupe
d'etude des lymphomes de l'adulte
Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoule
D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, Solal-
Celigny P, Salles G.
J Clin Oncol. 2010, 28(5):822-9.
La réflexion collective sur le sens du soin : une dimension essentielle en
hématologie
Bordessoule D
Hématologie, 2010, 16 (1) :80.
Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease
after allogeneic haematopoietic stem cell transplantation.
Chevallier P, Prebet T, Turlure P, Hunault M, Vigouroux S, Harousseau JL, Blaise D, Ifrah
N, Milpied N, Mohty M.
Bone Marrow Transplant. 2010, 45(1):165-70.

Communications orales et posters dans les congrès nationaux ou internationaux
Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study
De Renzis B, Wattel E, Beyne-Rauzy O, Knoops L, Boyer F, Cabrespine A, Raynaud S,
Rose C, Demory JL, Nguyen-Khac F, Ades L, Tertian G, Guièze R, Ianotto JC, Tournilhac
O, Bordessoule D, Cahn JY, Fontenay M, Kiladjian JJ, Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 440.
Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL -
First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss
APL Group
Ades L, Raffoux E, Chevret S, Pigneux A, Thomas X, Bordessoule D, Vey N, Guerci A,
Lamy T, Récher C, Muller B, Tournilhac O, Pautas C, Cahn JY, Delaunay J, Deconinck E,
Quesnel B, de Botton S, Stamatoullas A, Chomienne C, Dombret H, Degos L, Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 505.
Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with
Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d’Etude Des Lymphomes De
l’Adulte (GELA) Study LNH03-7B
Peyrade F, Jardin F, Gisselbrecht C, hyss A, Emile JF, Castaigne S, Coiffier B, Haioun C,
Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier
M, Salles B, Bosly A, Tilly H.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 853.
High Body Mass Index (BMI) as a Predictor of Differentiation Syndrome (DS) In
Acute Promyelocytic Leukemia (APL)
Jeddi R, Achour B, Guerci-Bresler A, Ghédira H, Dombret H, Huguet F, Chevallier P, Vey
N, de Botton S, Bordessoule D, Muller B, Eclache V, Gardin C, Meddeb B, Adès L,Pierre
Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 1078
Use of Cytarabine for Mantle Cell Lymphoma Treatment: 10 Years of Experience of a
French Haematology Department
Gourin MP, Abraham A, Trimoreau F, Petit B,Girault S, Olivrie A, Jaccard A, Feuillard
J, Bordessoule D.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts) 2010; 116: 1755.
Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS ?
Cereja S, Brechignac S, Ades L, Braun T, Boehrer S, Hebibi Z, Sapena R, Beyne-Rauzy
O, Vey N, Dombret H, Bordessoule D, Dreyfus F, Fenaux P, Gardin C.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 1868.
Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent
Cases, and Comparison with De Novo Cases
Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X,
Bordessoule D, Vey N, Guerci A, Lamy T, Récher C, Mueller B, Tournilhac O, PautasC,
Cahn JY, Delaunay J, Guyotat D, Deconinck E, Quesnel B, Stamatoullas A, Chomienne C,
Degos L, Dombret H, Fenaux P, Ades L.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 2171.
Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk,
Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone
Des Myelodysplasies (GFM)
Park S, Sapena R, Vassilieff D, Kelaidi C, Bordessoule D, Stamatoullas A, Cheze S,
Beyne-Rauzy O, Vey N, Rose C, Guerci A, Ame S, Tertian G, Slama B, Fenaux P, Dreyfus
F.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 2916.
Outpatient and Home Chemotherapy: Preliminary Results of the Experience of the
Limousin (France) Hematological Care Network
Touati M, Remenieras L, Moreau S, Truffinet V, Lefort S, Vergnenegre F, Abouelfadel
M, Lagarde A, Cournede A, Daulange A, Laffetas MC, Bordessoule D.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 3823.
Treatment of Advanced CMML by Azacitidine (AZA) In a Compassionate Program.
the GFM Experience In 38 Patients
Wolfromm A, Dreyfus F, Vey N, Delaunay J, Stamatoullas A, Banos A, Marfaing-Koka A,
de Botton S, Bordessoule D, Legros L,Beyne Rauzy O,Gyan E, Cony Makhoul P, Thepot
S, Itzykson R, Fenaux P, Ades L.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 4023.
Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or
Relapsing After Erythropoiesis Stimulating Agents (ESAs)
Kelaidi C, Park S, Sapena R, Beyne-Rauzy O, Coiteux V, Vey N, Stamatoullas A, Choufi
B, Delaunay J, Gourin MP, Cheze S, Ravoet C, Ferrant A, Escoffre-Barbe M, Aljassem L,
Raffoux E, Itzykson R, Ades L, Dreyfus F, Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 442.
Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose
Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of
the French Multicentric Randomized Trial
Jaccard A, Leblond V, Royer B, Leleu X, Delarue R, Kolb B, Deconinck E, Stamatoullas A,
Coppo P, Arnulf B, Hermine O, Moreau P, Fermand JP.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 1344.
Validation of the Criteria of Response to Treatment In AL Amyloidosis
Palladini G, Dispenzieri A, Gertz MA, Wechalekar A, Hawkins P, O Schonland S,
Hegenbart U, L. Comenzo R, Kastritis E, Dimopoulos M, Jaccard A, Klersy C, Merlini G.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 1364.
Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a
Randomized Trial (APL 2000) From the French Belgian Swiss APL Group
Ades L, Raffoux E, Chevret S, de Botton S, Guerci A, Pigneux A, Vey N, Lamy T, Huguet
F, Muller B, Maloisel F, Deconinck E, Caillot D, Gratecos N, Sotto JJ, Ferrant A, Turlure P,
Thomas X, Chevallier P, Ifrah N, Stamatoullas A, Chomienne C, Dombret H, Degos L,
Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 13.
Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without
Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)
Ades L, ebras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Visanica S, Turlure
P, Guerci A, Cabrol MP, Banos A, Blanc M, Ve Ny, Eclache V, Chevret S, Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 976.
Prognostic Impact of Wilms Tumor 1 Single Nucleotide Polymorphism rs16754 In
Older Patients with Acute Myeloid Leukemia
Renneville A, Boissel N, Helevaut N, Nibourel O, Terré C, Pautas C, Gardin C, Thomas X,
Turlure P, Reman O, Berthon C, Dombret H, Castaigne S, Preudhomme C.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 2701
A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk
MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial
Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Recher C,
Dartigeas C, Vey N, Legros L, Delaunay J, Salanoubat C, Visanica S, tamatoullas A,
Isnard F, Marfaing-Koka A, De Botton S, Chelgoum Y, Taksin AL, Plantier I, Ame S,
Boehrer S, Gardin C, Ades L, Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 3996.
Central Nervous System (CNS) at First Relapse In APL. A Report on 2 Multicenter
Trials
Ferini GA, Raffoux E, Guerci A, Pigneux A, Huguet F, Vey N, Lamy T, Muller B, Chevallier
P , Castaigne S, Turlure P, Ferrant A, Ifrah N, de Botton S, Dombret H, Ades L and
Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 1084.
Azacytidine (AZA) In Relapsed MDS and AML After Allogeneic Stem Cell
Transplantation (allo-HSCT): Results of the French ATU Program
Guièze R, Jouinot A, Itzykson R, Thepot S, Guillaume T, Coiteux V, Wittnebel S, de Botton
S, Dartigeas C, Sirvent A, Turlure P, Bouscary D, Robin M, Vernant JP, Sutton L, Dreyfus
F, Bay JO, Ades L, Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 1293.
A Pediatric Treatment of Ph-Negative Acute Lymphoblastic Leukemia (ALL) Is
Effective and Safe In Adolescents and Young Adults (AYAs) until 29 Years of Age
Cluzeau T, Dhedin N, Huguet F, Raffoux E, Maury S, Lamy T, Mannone L, Guillerm G,
Delannoy A, Turlure P, Norbert Vey N, Baruchel A, Dombret H, Boissel N
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 2125.
Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated
with Azacitidine (AZA)
Itzykson R, Thepot S, Beyne-Rauzy O, Quesnel B, Ame S, Turlure P, Harel S, Marfaing-
Koka A, Chelgoum Y, Stamatoullas A, Uzunov M, Ifrah N, Dombret H, Lionel Ades L, S.
Swern A, Gardin C, Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 2183.
AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60
Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM)
Fadlallah J, Bally C, Quesnel B, Vey N, Dreyfus F, Turlure P, de Botton S, Dartigeas C, de
Renzis B, Thepot S, Itzykson R, Fenaux P, Ades L.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 2911.
Lack of Correlation of Endospcopy Findings and Pathological Results In GI-GvHD
Abraham J, Janin A, Gornet JM, Robin M, Peffault de Latour R, Ribaud P, Mary JY,
Lemann M, Porcher R, Socie G.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 2339.
Left atrium enlargement is an independent predictor of overall mortality in patients
with systemic amyloidosis
Mohty D, P. Pibarot P, Darodes N, Lavergne D, Echahidi N, Virot P, Bordessoule D,
Jaccard A
Congrés international de cardiologie – 23-27 octobre 2010 – Montréal
Epidemiological review of lymphoma diagnosis in French rural area between 2003
and 2008
Touati M, Gourin MP, Abraham J, Weinbreck N, Gachard N, Olivrie-Gamaury A,
Feuillard J, Jaccard A, Bordessoule D.
ASCO, Chicago 4-8 juin 2010
J Clin Oncol 2010, 28:15s, (suppl; abstr 18551)

Collégialité et responsabilité médicale, vers un élargissement de ces notions et une
responsabilité partagée entre le mdecin et son patient.
Trarieux-Signol S, Moreau S, Gourin MP, Bordessoule D
SFAP 2010 - Marseille juin 2010 - Communication orale
Référence CH24-d Regard des soignants d’un service d’hématologie clinique sur la
loi relative aux droits des malades et à la fin de vie: analyse qualitative et
quantitative
Trarieux-Signol S, Gourin MP, Guillout J, Vigier D, Penot A, Moreau S, Bordessoule
D.
SFAP - Marseille juin 2010
Increased of overall survival (OS) and malignancies during tyrosine kinase
inhibitors (TKI) in a real life cohort of patients with a chronic myeloid leukemia
(CML).
Gourin MP,Turlure P,Gachard N, Girault S, Touati M, Abraham J, Pons E, Philippon C,
Feuillard J, Bordessoule D.
ASCO, Chicago 4-8 juin 2010
J Clin Oncol 2010, 28:15s, (suppl; abstr 6602).
Effectiveness of second line treatment in AL amyloidosis patients refractory to M-
Dex
Jaccard A, Abraham J, Debarri H, Penot A, Desport E, Aguilar C, Lavergne D, Auroy F,
Leleu X, Goldstein A, Kolb B, Bridoux F, Fermand JP, Leblond V.
12ème Congrès International de l’Amylose – 18-21 avril 2010 - Rome
Amyloid. 2010; 17: P-189.
Non invasive fibroscan detection of hepatic amyloidosis
Jaccard A, Cypierre A, Rousseau A, Yagoubi F, Abraham J, Lefebvre A, Loustaud-Ratti
V;
12ème Congrès International de l’Amylose - 18-21 avril 2010 - Rome
Amyloid. 2010; 17 (suppl1) : P-162.
Systemic AL amyloidosis with renal involvement in a region of Western France
Eric Moumas, Estelle Desport, Jean-Marc Gombert, Corinne Lacombe, Jean-Michel
Goujon, Arnaud Jaccard, Guy Touchard, Frank Bridoux
12ème Congrès International de l’Amylose - 18-21 avril 2010 - Rome
Amyloid. 2010; 17 (suppl1) : P-122.
Intérêt des bases de données pour améliorer les taux d'inclusion dans les
protocoles de recherche clinique en hématologie.
Gourin MP, Marin B, Fargeas JB, Philippon C, Bompart F, Tisseuil C, Jaccard A,
Preux PM, Bordessoule D.
Congrès 2010 de la Société Française d’Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 223 [14-05]
Un réseau de psychologues ville-hôpital PsyHématolim autour du patient atteint
d’hémopathie maligne : expérience d’une dérogation tarifaire en Limousin.
Touati M, Laffetas MC, Rampnoux E, Aubert K, Truffinet V, Rapp MJ, Moreau S,
Pechalat MP, Lefort S, Bordessoule D.
Congrès 2010 de la Société Française d’Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 222 [14-03]
La parole aux patients dans le réseau Hématolim : enquête de satisfaction sur les
consultations avancées.
Touati M, Rapp MJ, Truffinet V, Venot J, VaquiLaffetas MC, Rampnoux not S, Lo Re P,
Henner G, Tardieux J, Gourin MP, Laffetas MC, Bordessoule D.
Congrès 2010 de la Société Française d’Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 221 [14-02]
Intérêt du rituximab dans le purpura thrombotique thrombocytopénique en réponse
non optimale au traitement standard.
Froissard A, Veyradier A, Buffet M, Poullin P, Malot S, Galicier L, Bordessoule D, Vernant
J, Azoulay E, Guidet B, Wynckel A, Coppo P.
Congrès 2010 de la Société Française d’Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 200 [12-40]
Facteurs pronostiques de réponse et de survie globale chez 271 SMD de haut risque
(incluant des AREB-t) traités par azacytidine.
Itzykson R, Thépot S, Quesnel B, Beyne-Rauzy O, Dreyfus F, Turlure P, legros L,
Dartigeas C, Delaunay J, Gardin C, Adès L, Fenaux P.
Congrès 2010 de la Société Française d’Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 160 [09-02]
Etude de phase I de l’anticorps monoclonal Anti-Natural Killer Inhibitory Receptor
(KIR) IPH2101 en monothérapie dans la leucémie aiguë myéloïde du sujet âgé :
effets cliniques et immunologiques d’une dose unique suivie d’injections répétées.
Vey N, Bourhis JH, Dombret H, Bordessoule D,Prébet T, Charbonnier A, de Botton S,
Boissel N, d’Arnoux C, André P, Tiollier J,Squiban P, Blaise D, Olive D, Romagné F.
Congrès 2010 de la Société Française d’Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 137 [07-34]
Impact pronostique des mutations d’IDH1 et IDH2 dans les leucémies aiguës
myéloblastiques à caryotype normal. Etude du groupe ALFA (Acute Leukemia
French Association).
Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Bordessoule D, Pautas C,
Terré C, Thomas X, Castaigne S, Dombret H, Preudhomme C.
Congrès 2010 de la Société Française d’Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 120 [07-01]
Etude de phase II de l’association ACBVP + bortezomib dans le traitement de
première ligne des lymphomes T ou à cellules NK : résultats définitifs du protocole
GELA LNH05-1T.
Delmer A, Fitoussi O, Goulard P, Laurent G, Jaccard A, Morschhauser F, Ferme C, Tilly
H, Gisselbrecht C, Coiffier B.
Congrès 2010 de la Société Française d’Hématologie
Hématologie, 2010 (spécial 1) ; 16 : p 84 [05-60]
Lymphomes non hodgkiniens et diabète de type 2 chez les sujets âgés : impact sur
la prise en charge dans la vraie vie.
Moreau S, Gourin MP, Remenieras L, Touati M, Bompart F, Olivrie A, Weinbreck N,
Lefort S, Devesa-Mansour D, Feuillard J, Jaccard A, Bordessoule D.
Congrès 2010 de la Société Française d’Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 82 [05-56]
Résultats préliminaires de l’intérêt de la tomoscintigraphie au MIBI pour la
prédiction de la réponse à la chimiothérapie lors du bilan initial des lymphomes de
haut grade et des maladies de Hodgkin : à propos d’une étude prospective de 81
patients.
Gourin MP, Monteil J, Marin B, Girault S, Dmytruck N, Abraham J, Olivrie-Gamaury A,
Weinbreck N, Jaccard A, Feuillard J, Bordessoule D.
Congrès 2010 de la Société Française d’Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 71 [05-35]
Traitement séquentiel par rituximab puis CHOP+G-CSF des lymphoproliférations
post-transplantation : résultats de l’étude de phase II multicentrique prospective
européenne « LPT1 ».
Choquet S, Oertel S, Leblond V, Morschhauser F, Lamy T, Jaccard A, Salles G,
Bouabdallah R, Suarez F, Lebranchu Y, Vande E, Trappe RU.
Congrès 2010 de la Société Française d’Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 56 [05-04]
La réflexion collective sur le sens du soin : une dimension essentielle en
hématologie
Bordessoule D.
Congrès 2010 de la Société Française d’Hématologie. Communication orale
Remerciements pour participation comme centre investigateur
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F,
Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A,
Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V,
Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes
Chroniques (Fi-LMC).
N Engl J Med. 2010, 363(26):2511-2.
Higher incidence of relapse in patients with acute myelocytic leukemia infused with
higher doses of CD34+ cells from leukapheresis products autografted during the
first remission.
Gorin NC, Labopin M, Reiffers J, Milpied N, Blaise D, Witz F, de Witte T, Meloni G, Attal M,
Bernal T, Rocha V; Acute Leukemia Working Party, European Cooperative Group for
Blood and Marrow Transplantation.
Blood. 2010, 116(17):3157-62.
Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup
analysis of 116 patients from the EPIC trial.
Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, Domokos G, Roubert B, Porter
JB; EPIC study investigators.
Blood. 2010, 116(14):2448-54.

B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype
of the disease.
Mouillot G, Carmagnat M, Gérard L, Garnier JL, Fieschi C, Vince N, Karlin L, Viallard JF,
Jaussaud R, Boileau J, Donadieu J, Gardembas M, Schleinitz N, Suarez F, Hachulla E,
Delavigne K, Morisset M, Jacquot S, Just N, Galicier L, Charron D, Debré P, Oksenhendler
E, Rabian C; DEFI Study Group.
J Clin Immunol. 2010, 30(5):746-55.
Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and
prednisone derived regimens in patients aged under 60 years with low-intermediate
risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol.
Morel P, Munck JN, Coiffier B, Gisselbrecht C, Ranta D, Bosly A, Tilly H, Quesnel B, Thyss A, Mounier N, Brière J, Molina T, Reyes F; Groupe d'Etude de Lymphomes des l'Adulte (GELA). Leuk Lymphoma. 2010, 51(9):1668-77. Deferasirox in iron-overloaded patients with transfusion-dependent
myelodysplastic syndromes: Results from the large 1-year EPIC study.
Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M,
Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C; EPIC study investigators.
Leuk Res. 2010, 34(9):1143-50.
The French national registry of primary immunodeficiency diseases.
CEREDIH: The French PID study group.
Clin Immunol. 2010, 135(2):264-72.
HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related
idiopathic thrombotic thrombocytopenic purpura in Caucasians.
Coppo P, Busson M, Veyradier A, Wynckel A, Poullin P, Azoulay E, Galicier L, Loiseau P;
French Reference Centre For Thrombotic Microangiopathies.
J Thromb Haemost. 2010, 8(4):856-9.
Evaluation of hemostasis and endothelial function in patients with paroxysmal
nocturnal hemoglobinuria receiving eculizumab.
Helley D, de Latour RP, Porcher R, Rodrigues CA, Galy-Fauroux I, Matheron J, Duval A,
Schved JF, Fischer AM, Socié G; French Society of Hematology.
Haematologica. 2010, 95(4):574-81.

Source: http://hematolim.fr/Portals/0/Publications/PUBLI%202010.pdf